1-hexadecyl-2-acetyl-glycero-3-phosphocholine has been researched along with pms 601 in 4 studies
| Studies (1-hexadecyl-2-acetyl-glycero-3-phosphocholine) | Trials (1-hexadecyl-2-acetyl-glycero-3-phosphocholine) | Recent Studies (post-2010) (1-hexadecyl-2-acetyl-glycero-3-phosphocholine) | Studies (pms 601) | Trials (pms 601) | Recent Studies (post-2010) (pms 601) |
|---|---|---|---|---|---|
| 9,156 | 187 | 552 | 6 | 0 | 0 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bensaid, O; Clayette, P; Dereuddre-Bosquet, N; Dong, CZ; Dormont, D; Godfroid, JJ; Heymans, F; Huet, J; Kan, E; Lamouri, A; Martin, M; Redeuilh, C; Serradji, N | 1 |
| Bensaïd, O; Clayette, P; Dereuddre-Bosquet, N; Dormont, D; Fichet, G; Godfroid, JJ; Heymans, F; Lamouri, A; Martin, M; Serradji, N | 1 |
| Bensaid, O; Cisternino, S; Clayette, P; Dereuddre-Bosquet, N; Dong, CZ; Dormont, D; Heymans, F; Huet, J; Lamouri, A; Martin, M; Redeuilh, C; Rousselle, C; Scherrmann, JM; Serradji, N | 1 |
| Clayette, P; Dash, PK; Dong, CZ; Dou, H; Eggert, D; Gelbard, HA; Gendelman, HE; Gorantla, S; Heymans, F; Poluektova, L; Serradji, N | 1 |
4 other study(ies) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and pms 601
| Article | Year |
|---|---|
Structure-activity relationships in platelet-activating factor (PAF). 10. From PAF antagonism to inhibition of HIV-1 replication.
Topics: Anti-HIV Agents; Cells, Cultured; HIV; Humans; In Vitro Techniques; Inhibitory Concentration 50; Macrophages; Microbial Sensitivity Tests; Piperazines; Platelet Activating Factor; Platelet Membrane Glycoproteins; Pyridines; Receptors, Cell Surface; Receptors, G-Protein-Coupled; Structure-Activity Relationship; Thiazoles; Virus Replication | 2000 |
[Antiretroviral ant anti-inflammatory properties of a novel platelet activation factor antagonist, PMS-601].
Topics: Anti-HIV Agents; Anti-Inflammatory Agents; CD4 Antigens; HIV-1; Humans; Macrophages; Piperazines; Platelet Activating Factor; Receptors, CCR5 | 2000 |
Structure-activity relationships in platelet-activating factor. 12. Synthesis and biological evaluation of platelet-activating factor antagonists with anti-HIV-1 activity.
Topics: Animals; Anti-HIV Agents; Biological Availability; Blood-Brain Barrier; Carbamates; Cells, Cultured; HIV-1; Humans; In Vitro Techniques; Macrophages; Male; Mice; Permeability; Piperazines; Platelet Activating Factor; Platelet Aggregation; Rabbits; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Virus Replication | 2004 |
Development of a platelet-activating factor antagonist for HIV-1 associated neurocognitive disorders.
Topics: AIDS Dementia Complex; Animals; Anti-Inflammatory Agents; Brain; Cell Death; Cells, Cultured; Cognition Disorders; Disease Models, Animal; Focal Adhesion Kinase 2; Giant Cells; Gliosis; Humans; Immunologic Factors; Inflammation Mediators; Male; Mice; Mice, SCID; Microglia; Monocytes; NF-kappa B; Piperazines; Platelet Activating Factor | 2009 |